These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 8562301)

  • 1. Evidence for the polymorphic oxidation of debrisoquine and proguanil in a Khmer (Cambodian) population.
    Wanwimolruk S; Thou MR; Woods DJ
    Br J Clin Pharmacol; 1995 Aug; 40(2):166-9. PubMed ID: 8562301
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genetic polymorphism of debrisoquine (CYP2D6) and proguanil (CYP2C19) in South Pacific Polynesian populations.
    Wanwimolruk S; Bhawan S; Coville PF; Chalcroft SC
    Eur J Clin Pharmacol; 1998 Jul; 54(5):431-5. PubMed ID: 9754989
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Polymorphic oxidative metabolism of proguanil in a Nigerian population.
    Bolaji OO; Sadare IO; Babalola CP; Ogunbona FA
    Eur J Clin Pharmacol; 2002 Nov; 58(8):543-5. PubMed ID: 12451432
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evidence for the polymorphic oxidation of debrisoquine and proguanil in a New Zealand Maori population.
    Wanwimolruk S; Pratt EL; Denton JR; Chalcroft SC; Barron PA; Broughton JR
    Pharmacogenetics; 1995 Aug; 5(4):193-8. PubMed ID: 8528265
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evidence for the polymorphic oxidation of debrisoquine in the Thai population.
    Wanwimolruk S; Patamasucon P; Lee EJ
    Br J Clin Pharmacol; 1990 Feb; 29(2):244-7. PubMed ID: 2306417
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Proguanil metabolism in relation to S-mephenytoin oxidation in a Turkish population.
    Basci NE; Bozkurt A; Kortunay S; Isimer A; Sayal A; Kayaalp SO
    Br J Clin Pharmacol; 1996 Dec; 42(6):771-3. PubMed ID: 8971434
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Debrisoquine and mephenytoin oxidation in Sinhalese: a population study.
    Weerasuriya K; Jayakody RL; Smith CA; Wolf CR; Tucker GT; Lennard MS
    Br J Clin Pharmacol; 1994 Nov; 38(5):466-70. PubMed ID: 7893590
    [TBL] [Abstract][Full Text] [Related]  

  • 8. S-mephenytoin, sparteine and debrisoquine oxidation: genetic polymorphisms in a Turkish population.
    Basci NE; Brosen K; Bozkurt A; Isimer A; Sayal A; Kayaalp SO
    Br J Clin Pharmacol; 1994 Nov; 38(5):463-5. PubMed ID: 7893589
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The activation of the biguanide antimalarial proguanil co-segregates with the mephenytoin oxidation polymorphism--a panel study.
    Ward SA; Helsby NA; Skjelbo E; Brøsen K; Gram LF; Breckenridge AM
    Br J Clin Pharmacol; 1991 Jun; 31(6):689-92. PubMed ID: 1867963
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metoprolol metabolism and debrisoquine oxidation polymorphism--population and family studies.
    McGourty JC; Silas JH; Lennard MS; Tucker GT; Woods HF
    Br J Clin Pharmacol; 1985 Dec; 20(6):555-66. PubMed ID: 2868742
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of omeprazole and cimetidine on the urinary metabolic ratio of proguanil in healthy volunteers.
    Somogyi AA; Reinhard HA; Bochner F
    Eur J Clin Pharmacol; 1996; 50(5):417-9. PubMed ID: 8839666
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Debrisoquine oxidation in a Finnish population: the effect of oral contraceptives on the metabolic ratio.
    Kallio J; Lindberg R; Huupponen R; Iisalo E
    Br J Clin Pharmacol; 1988 Dec; 26(6):791-5. PubMed ID: 3242585
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Correlations among the metabolic ratios of three test probes (metoprolol, debrisoquine and sparteine) for genetically determined oxidation polymorphism in a Japanese population.
    Horai Y; Taga J; Ishizaki T; Ishikawa K
    Br J Clin Pharmacol; 1990 Jan; 29(1):111-5. PubMed ID: 2297455
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Polymorphism of debrisoquine and mephenytoin hydroxylation among Estonians.
    Kiivet RA; Svensson JO; Bertilsson L; Sjöqvist F
    Pharmacol Toxicol; 1993 Feb; 72(2):113-5. PubMed ID: 8474964
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Debrisoquine oxidation polymorphism in a Tasmanian population.
    Veronese ME; McLean S
    Eur J Clin Pharmacol; 1991; 40(5):529-32. PubMed ID: 1884730
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relation between debrisoquine oxidation phenotype and morphological, biological, and pathological variables in a large population.
    Vincent-Viry M; Muller J; Fournier B; Galteau MM; Siest G
    Clin Chem; 1991 Mar; 37(3):327-32. PubMed ID: 2004438
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Polymorphic debrisoquin metabolism in a Turkish population.
    Bozkurt A; Basci NE; Isimer A; Sayal A; Kayaalp SO
    Clin Pharmacol Ther; 1994 Apr; 55(4):399-401. PubMed ID: 8162666
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The multiple dose pharmacokinetics of proguanil.
    Helsby NA; Edwards G; Breckenridge AM; Ward SA
    Br J Clin Pharmacol; 1993 Jun; 35(6):653-6. PubMed ID: 8329294
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Debrisoquine oxidation in an Italian population: a study in healthy subjects and in schizophrenic patients.
    Spina E; Campo GM; Calandra S; Caputi AP; Carrillo JA; Benitez J
    Pharmacol Res; 1992 Jan; 25(1):43-50. PubMed ID: 1738757
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Debrisoquine oxidation phenotype and susceptibility to lung cancer.
    Speirs CJ; Murray S; Davies DS; Biola Mabadeje AF; Boobis AR
    Br J Clin Pharmacol; 1990 Jan; 29(1):101-9. PubMed ID: 2153391
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.